{"protocolSection":{"identificationModule":{"nctId":"NCT03655964","orgStudyIdInfo":{"id":"3418"},"organization":{"fullName":"Aristotle University Of Thessaloniki","class":"OTHER"},"briefTitle":"Effect of Olmesartan and Nebivolol on Ambulatory Blood Pressure and Arterial Stiffness in Acute Stage of Ischemic Stroke","officialTitle":"Olmesartan Versus Nebivolol in Management of Hypertension in Acute Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2020-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-08-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-08-20","type":"ACTUAL"},"completionDateStruct":{"date":"2019-08-20","type":"ACTUAL"},"studyFirstSubmitDate":"2018-08-30","studyFirstSubmitQcDate":"2018-08-30","studyFirstPostDateStruct":{"date":"2018-09-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-01-06","lastUpdatePostDateStruct":{"date":"2020-01-07","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Vaios Vasileios","investigatorTitle":"Principal Investigator, Division of Nephrology and Hypertension, 1st Department of Medicine, AHEPA University Hospital","investigatorAffiliation":"Aristotle University Of Thessaloniki"},"leadSponsor":{"name":"Aristotle University Of Thessaloniki","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Single-blind, randomized, active-treatment controlled clinical study evaluating the effect of omesartan and nebivolol versus no treatment on 24-hour brachial and central aortic blood pressure in hypertensive patients with acute ischemic stroke","detailedDescription":"A total of 60 patients with hypertension and acute ischemic stroke (clinic BP \\>160/100 mmHg and \\<220/120 mmHg at day 3 of stroke onset) will be randomly allocated to therapy with olmesartan (20 mg/day) or nebivolol (5 mg/day) or no treatment between the 3rd to 7th day of hospitalization."},"conditionsModule":{"conditions":["Stroke, Ischemic"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":60,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Olmesartan","type":"EXPERIMENTAL","description":"20 patients randomly allocated to single-blind antihypertensive therapy with olmesartan (20 mg/day)","interventionNames":["Drug: Olmesartan"]},{"label":"Nebivolol","type":"EXPERIMENTAL","description":"20 patients randomly allocated to single-blind antihypertensive therapy with nebivolol (5 mg/day)","interventionNames":["Drug: Nebivolol"]},{"label":"No antihypertensive treatment","type":"EXPERIMENTAL","description":"20 patients randomly allocated to receive no antihypertensive therapy during the acute stage of ischemic stroke","interventionNames":["Other: No antihypertensive treatment"]}],"interventions":[{"type":"DRUG","name":"Olmesartan","description":"At Day 4 of stroke onset, patients with clinic BP \\>160/100 mmHg will receive olmesartan 20 mg once daily until Day 7 of stroke onset","armGroupLabels":["Olmesartan"],"otherNames":["No other intervention"]},{"type":"DRUG","name":"Nebivolol","description":"At Day 4 of stroke onset, patients with clinic BP \\>160/100 mmHg will receive nebivolol 5mg once daily until Day 7 of stroke onset","armGroupLabels":["Nebivolol"],"otherNames":["No other intervention"]},{"type":"OTHER","name":"No antihypertensive treatment","description":"Patients will be left without treatment","armGroupLabels":["No antihypertensive treatment"],"otherNames":["No other intervention"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Between-group difference in change of 24-hour brachial BP","description":"24-hour ambulatory BP monitoring with the Mobil-O-Graph device (IEM, Germany) at baseline (Day 3 of stroke onset) and study-end (Day 7 of stroke onset)","timeFrame":"Day 3 until Day 7 of stroke onset"}],"secondaryOutcomes":[{"measure":"Between-group difference in change of 24-hour pulse wave velocity","description":"24-hour ambulatory BP monitoring with the Mobil-O-Graph device (IEM, Germany) at baseline (Day 3 of stroke onset) and study-end (Day 7 on stroke onset)","timeFrame":"Day 3 until Day 7 of stroke onset"},{"measure":"Between-group difference in change of 24-hour augmentation index","description":"24-hour ambulatory BP monitoring with the Mobil-O-Graph device (IEM, Germany) at baseline (Day 3 of stroke onset) and study-end (Day 7 on stroke onset)","timeFrame":"Day 3 until Day 7 of stroke onset"},{"measure":"Between-group difference in 24-hour central aortic BP","description":"24-hour ambulatory BP monitoring with the Mobil-O-Graph device (IEM, Germany) at baseline (Day 3 of stroke onset) and study-end (Day 7 on stroke onset)","timeFrame":"Day 3 until Day 7 of stroke onset"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients with a first diagnosis of an acute ischemic stroke (permanent or transient)\n2. BP levels \\>160/100mmHg at start of the third day of hospitalization\n3. BP levels \\>160/100mmHg and \\<220/120mmHg at start of the fourth day of hospitalization\n\nExclusion Criteria:\n\n1. Patients with confirmed hemorrhagic stroke with computer tomography at hospital admission.\n2. Patients with chronic atrial fibrillation or other cardiac arrhythmia.\n3. Patients with BP levels \\>220/120 mmHg during the hospitalization or patients with other hypertensive emergency situation (i.e. acute myocardial ischemia, aortic dissection, acute pulmonary edema, acute renal failure, hypertensive encephalopathy) which demands fast BP reduction with the use of intravenous antihypertensive drugs, according to current guidelines {Jauch, 2013 340 /id}.\n4. Patients with specific indication for treatment with blockers of the renin-angiotensin-aldosterone system (RAAS) other than hypertension (i.e., congestive heart failure, acute myocardial ischemia).\n5. Patients with specific indication for treatment with β-blockers other than hypertension (i.e., heart failure, tachyarrhythmia or angina pectoris).\n6. Patients with specific contra-indications for RAAS blockers (hyperkalemia, history of angioedema) and patients with a history of allergic reaction or severe hypotension after olmesartan treatment.\n7. Patients with specific contra-indications for β-blockers (heart rate \\<60/min without a treatment with bradyarrhythmic drugs), chronic obstructive pulmonary disease or asthma and patients with history of allergic reaction after nebivolol treatment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Eleni Georgianou, MD","affiliation":"School of Medicine, Aristotle University of Thessaloniki","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"AHEPA University Hospital","city":"Thessaloniki","zip":"54621","country":"Greece","geoPoint":{"lat":40.64361,"lon":22.93086}}]},"referencesModule":{"references":[{"pmid":"29637385","type":"BACKGROUND","citation":"Lobanova I, Qureshi AI. Blood Pressure Goals in Acute Stroke-How Low Do You Go? Curr Hypertens Rep. 2018 Apr 10;20(4):28. doi: 10.1007/s11906-018-0827-5."},{"pmid":"29621070","type":"BACKGROUND","citation":"Gasecki D, Coca A, Cunha P, Hering D, Manios E, Lovic D, Zaninelli A, Sierra C, Kwarciany M, Narkiewicz K, Karaszewski B. Blood pressure in acute ischemic stroke: challenges in trial interpretation and clinical management: position of the ESH Working Group on Hypertension and the Brain. J Hypertens. 2018 Jun;36(6):1212-1221. doi: 10.1097/HJH.0000000000001704."},{"pmid":"23370205","type":"BACKGROUND","citation":"Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013 Mar;44(3):870-947. doi: 10.1161/STR.0b013e318284056a. Epub 2013 Jan 31."},{"pmid":"31687205","type":"DERIVED","citation":"Georgianou E, Georgianos PI, Petidis K, Markakis K, Zografou I, Karagiannis A. Effect of Nebivolol and Olmesartan on 24-Hour Brachial and Aortic Blood Pressure in the Acute Stage of Ischemic Stroke. Int J Hypertens. 2019 Oct 7;2019:9830295. doi: 10.1155/2019/9830295. eCollection 2019."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M9714","name":"Hypertension","relevance":"LOW"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000437965","term":"Olmesartan"},{"id":"D000068577","term":"Nebivolol"},{"id":"D000000959","term":"Antihypertensive Agents"}],"ancestors":[{"id":"D000047228","term":"Angiotensin II Type 1 Receptor Blockers"},{"id":"D000057911","term":"Angiotensin Receptor Antagonists"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000014665","term":"Vasodilator Agents"},{"id":"D000058665","term":"Adrenergic beta-1 Receptor Agonists"},{"id":"D000000318","term":"Adrenergic beta-Agonists"},{"id":"D000000322","term":"Adrenergic Agonists"},{"id":"D000018663","term":"Adrenergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M276","name":"Nebivolol","asFound":"IBS","relevance":"HIGH"},{"id":"M3967","name":"Antihypertensive Agents","asFound":"Preferred","relevance":"HIGH"},{"id":"M91712","name":"Olmesartan","asFound":"Burst","relevance":"HIGH"},{"id":"M273","name":"Olmesartan Medoxomil","relevance":"LOW"},{"id":"M3822","name":"Angiotensin II","relevance":"LOW"},{"id":"M289298","name":"Giapreza","relevance":"LOW"},{"id":"M3825","name":"Angiotensinogen","relevance":"LOW"},{"id":"M25479","name":"Angiotensin II Type 1 Receptor Blockers","relevance":"LOW"},{"id":"M28606","name":"Angiotensin Receptor Antagonists","relevance":"LOW"},{"id":"M17102","name":"Vasodilator Agents","relevance":"LOW"},{"id":"M20436","name":"Adrenergic Agents","relevance":"LOW"},{"id":"M3360","name":"Adrenergic beta-Agonists","relevance":"LOW"},{"id":"M3363","name":"Adrenergic Agonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnAg","name":"Antihypertensive Agents"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaCoAg","name":"Vasoconstrictor Agents"}]}},"hasResults":false}